A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions
PHASE1CompletedINTERVENTIONAL
Enrollment
20
Participants
Timeline
Start Date
October 31, 2010
Primary Completion Date
November 30, 2010
Study Completion Date
February 28, 2011
Conditions
Acid RefluxGastro Oesophageal Reflux Disease
Interventions
DRUG
Zegerid
DRUG
Losec
Trial Locations (1)
BT2 7BA
Bio-Kinetic Europe Limited, 14 Great Victoria Street, Belfast BT2 7BA, Belfast